AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04565730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grup I= General anesthesia group
Description: Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys.
Study NCT04565730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grup II= Spinal anesthesia group
Description: Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys.
Study NCT01082939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
Study NCT01082939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
Study NCT01082939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
Study NCT01082939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours
Study NCT04490148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT02895555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-FACTOR
Description: Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
Study NCT02895555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Approx 50 g of allograft bone in the fused site
Study NCT04124757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
Study NCT04490148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT04490148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT04490148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Respiratory Health Coaching (NRHC)
Description: Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model.
Study NCT04691973 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health and lifestyle tool
Description: Health and lifestyle tool used online
Study NCT04691973 — intervention group
Intervention type: OTHER
Intervention: Usual care
Description: Usual care at ordinary healthcare provider
Study NCT03718793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral exhaled nitric oxide
Description: Small airway inflammation and dysfunction will be measured using the above mentioned tests.
Study NCT03610698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAF Positive Emotion Intervention
Description: 5-week online intervention teaching 8 positive emotions skills for caregivers
Study NCT02353637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partial Meal Replacements
Description: The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
Study NCT03610698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Reporting Control Condition
Description: Daily reporting of emotions for participants assigned to the control condition.
Study NCT04103736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It Sport Shot
Description: Source of naturally occurring dietary nitrates
Study NCT04103736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted placebo
Description: Placebo
Study NCT03817736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Procedure of TACE will be standardized.
Study NCT03817736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
Study NCT03817736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitor
Description: An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
Study NCT03248011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Lower extremity flexibility exercises will be performed
Study NCT03248011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Eccentric hamstring strengthening exercises will be performed
Study NCT03248011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular
Description: Dynamic lower extremity balance and movement control exercises will be performed
Study NCT00431808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]
Description: 3 doses of AMA 1 vaccine
Study NCT00431808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1
Description: 50 micrograms of AMA1
Study NCT03948659 — intervention group
Intervention type: PROCEDURE
Intervention: Arterio ventricular coupling
Description: We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
Study NCT04148924 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours).
Study NCT04148924 — intervention group
Intervention type: OTHER
Intervention: Medical staff questionnaire
Description: Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms
Study NCT02592772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Non-Menthol (RNC)
Description: Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
Study NCT02592772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Menthol (RNC-Men)
Description: Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
Study NCT02592772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Nicotine Non-Menthol (CN)
Description: Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
Study NCT02330952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40mg/day per os for 5 days
Study NCT02330952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg/day per os for 5 days
Study NCT03653026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration
Study NCT03653026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet for oral administration
Study NCT03653026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral administration
Study NCT02405572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula
Description: infant formulas
Study NCT04241133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The UnProcessed Pantry Project (UP3)
Description: UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
Study NCT01104090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC direct laryngoscopy
Description: Patients will be intubated using C-MAC with direct laryngoscopy.
Study NCT01104090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC Indirect laryngoscopy
Description: Patients will be intubated using C-MAC with indirect laryngoscopy.
Study NCT00151216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2CUhCLN2 (3x10^12 particle units)
Description: gene transfer; one-time administration via neuro surgery procedure
Study NCT03936933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg Injection
Description: 3.6 mg, Subcutaneously at every 28 days
Study NCT03936933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX® 3.6mg Injection
Description: 3.6 mg, Subcutaneously at every 28 days
Study NCT01755117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic, femoral, obturator nerve blocks
Study NCT01755117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block, posterior lumbar plexus block
Study NCT04421976 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEEP
Description: Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
Study NCT04421976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
Study NCT00551616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB-2914
Description: Single dose
Study NCT00551616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Single dose
Study NCT01380106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide 15mg
Description: Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
Study NCT01380106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide 25mg
Description: Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
Study NCT02422927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination
Description: red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
Study NCT02422927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
Study NCT02422927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
Study NCT02422927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00965705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Individual Therapy and Group Therapy
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaxelis™
Description: Intramuscular 0.5 mL single dose
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxelis™
Description: Intramuscular 0.5 mL single dose
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: Subcutaneous 0.5 mL single dose
Study NCT04606251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
Study NCT00290732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraductal arm
Description: Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
Study NCT00290732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous arm
Description: Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
Study NCT00548119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoCart
Description: autologous tissue implant
Study NCT00548119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: microfracture
Study NCT00964366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin and benzoyl peroxide
Description: Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
Study NCT00964366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone gel
Description: Twice-daily applications of dapsone gel
Study NCT02116829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Danish butter
Description: The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
Study NCT02116829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Study NCT02887313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
Study NCT02887313 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
Study NCT02909699 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: Subcutaneous 0.5 mL single dose
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: Subcutaneous 0.5 mL single dose
Study NCT04016714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: Subcutaneous 0.5 mL single dose
Study NCT01772654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Spin Labeled (ASL) MRI sequence
Description: The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence.
Study NCT01772654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeled (ASL) MRI sequence
Description: The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence.
Study NCT00895505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Phenprocoumon 3 mg, tablet, INR adjusted
Study NCT00895505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin-Natrium
Description: Warfarin-Natrium 5 mg, tablet, INR adjusted
Study NCT03814759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 + cisplatin
Description: S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
Study NCT03814759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation 45Gy per 5 weeks
Study NCT01706185 — intervention group
Intervention type: OTHER
Intervention: Data acquisition and analysis
Description: Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
Study NCT00572819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
Study NCT00572819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
Study NCT03225404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epte group
Description: Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
Study NCT03225404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling group
Description: The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.